Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2004

01-11-2004

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs

Authors: Susan M. Chang, John Kuhn, Patrick Wen, Harry Greenberg, David Schiff, Charles Conrad, Karen Fink, H. Ian Robins, Timothy Cloughesy, Lisa De Angelis, Jeffrey Razier, Kenneth Hess, Janet Dancey, Michael D. Prados

Published in: Investigational New Drugs | Issue 4/2004

Login to get access
Metadata
Title
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
Authors
Susan M. Chang
John Kuhn
Patrick Wen
Harry Greenberg
David Schiff
Charles Conrad
Karen Fink
H. Ian Robins
Timothy Cloughesy
Lisa De Angelis
Jeffrey Razier
Kenneth Hess
Janet Dancey
Michael D. Prados
Publication date
01-11-2004
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 4/2004
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/B:DRUG.0000036685.72140.03

Other articles of this Issue 4/2004

Investigational New Drugs 4/2004 Go to the issue

OriginalPaper

Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma

OriginalPaper

A phase I surrogate endpoint study of SU6668 in patients with solid tumors

OriginalPaper

Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer

OriginalPaper

Inhibitory effect of polypeptide from Chlamys farreri on UVA-induced apoptosis in human keratinocytes

OriginalPaper

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo

OriginalPaper

Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: Results of a phase II study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits